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Gabapentin for acute and 
chronic post-surgical pain
ABSTRACT
Pain after surgery remains a significant clinical problem as it impairs recovery adversely and may lead to the transition to 
chronic pain. Opioid medications are far from ideal agents in suppressing postoperative pain. Gabapentin –an anticonvul-
sant with antihyperalgesic properties- originally efficacious against neuropathic pain seems to be very promising for the 
management of pain after surgery as well. Gabapentin, by decreasing noxious stimulus-induced excitatory neurotransmitter 
release at the spinal cord, may attenuate central sensitization, and eventually decrease postoperative late pain. Furthermore, 
different sites of action may be pertinent to a synergistic effect with opioids. Both actions (antihyperalgesic effect and syn-
ergy with opioid analgesia) may manifest as analgesia and/or opioid-sparing effect after surgery. This has been confirmed 
by a variety of clinical studies, in a variety of settings. Most of these studies have shown that either single preoperative or 
repeated doses of gabapentin, continued for up to a few days after surgery, decrease acute postoperative pain and/or 
need for postoperative opioids. This has been shown for procedures such as abdominal and vaginal hysterectomy, breast 
surgery for cancer (mastectomy or lumpectomy), lumbar discectomy and spinal fusion, laparoscopic cholecystectomy and 
other, such as ENT surgery. Finally, a few studies indicate that perioperative gabapentin may as well decrease chronic pain 
several weeks after surgery.
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Pain is a common postoperative symp-
tom impairing the quality of postopera-
tive recovery, delaying discharge from 
Post-anaesthesia care unit (PACU) or 
surgical centre, leading to post-dis-
charge readmissions, and increasing 
overall morbidity and costs (1-4). 
Ongoing, acute postoperative pain may 
lead to chronic pain after surgery. Acute 
postoperative pain may be followed by 
persistent pain in a significant percent-
age of individuals after common surgi-
cal procedures (5,6). This persistent 
pain may last for more than 3-6 months 
after surgery (5). Specifically, stump 
and phantom pain may complicate limb 
amputations in 5-60% and 30-80% of 
patients respectively, while the inci-
dence of chronic postsurgical pain may 
range from 50-90% after breast surgery 
for cancer (7-9). Chronic pain is also 
common after thoracotomy (20-70%), 
inguinal hernia repair (up to 35%), and 
cholecystectomy (5-50%) (5,6). Under-
lying mechanisms may be pertinent 
to prolonged afferent input of nocic-
eptive signals, originating from surgi-
cal trauma (particularly injury affecting 
nerves) and perioperative inflammatory 
mechanisms, subsequently leading to 
alterations mediated by neural plas-
ticity, and eventually central sensiti-
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zation producing chronic pain. Kehlet 
et al have recognized that iatrogenic 
neuropathic injury is the most impor-
tant cause of chronic pain after sur-
gery (5). Furthermore, in the majority 
of patients, chronic post-surgical pain 
closely resembles with neuropathic 
pain (5). These include spontaneous 
painful sensations within or beyond an 
operated area (described as paroxys-
mal lancination, shooting, burning and 
throbbing pain), hyperalgesia, allody-
nia, different types of dysesthesia, as 
well as sensory loss within the area 
innervated by the damaged nerves.
Risk factors to transition to chronic pain 
in surgical patients are genetic sus-
ceptibility, various psychological and 
social factors, age and gender, and the 
intensity of preceding acute postop-
erative pain. The intensity of acute pain 
immediately before or after surgery is 
strongly associated with the incidence 
and intensity of subsequent chronic 
post-surgical pain after amputation, 
after breast surgery, thoracotomy and 
herniorrhaphy (10). Thus, suppres-
sion of this afferent nociceptive traffic 
by appropriate analgesic strategies, 
in addition to reducing postoperative 
pain, may suppress the development 
of chronic pain after surgery.
The association between intensity of 
acute postoperative pain and devel-
opment of chronic pain after surgery 
implies that inadequate peri- and post-
operative analgesia may constitute a 
significant factor. Thus, in this context, 
effective pain management should be 
considered as an essential compo-
nent of anaesthesia and perioperative 
medicine. Various surveys have esti-
mated the percentage of patients who 
experience pain after surgery to range 
between 30 and 80%, and, of these 
patients, the majority (more than 80%) 
report the intensity as moderate, severe, 
or extreme (11). 
Traditionally, opioid analgesics have 
been considered as the mainstay of 
management of moderate to severe 
postoperative pain. Advantages of these 
drugs include their established efficacy, 
wide availability, experience with their 
use, and relative ease of administration. 
However, side effects such as respirato-
ry depression and hypoxemia, nausea 
and vomiting, sedation, and delayed 
recovery of  bowel function are limita-
tions of their use. The emerging recog-
nition of opioid-induced hyperalgesia 
is an additional drawback: it has been 
shown that repeated administration of 
opioids intraoperatively induce an acute 
state of tolerance, hyperalgesia, or both 
(12-15). The pathophysiology of opioid-
induced hyperalgesia is complex, but 
phenomena of peripheral and central 
sensitization may be highly pertinent. 
Mechanisms related to N-Methyl-D-
Aspartate (NMDA) receptor activation 
and translocation of the protein kinase 
C (PKC) in dorsal horn neurons have 
been implicated in the development of 
persisting pain, hyperalgesia, and toler-
ance to opioid analgesia (16-18). Opioid 
receptor activation results in stimulation 
of PKC, which phosphorylates several 
target proteins, including the NMDA 
receptor, with subsequent downstream 
activation of a series of cascades that 
mediate central sensitization and hyper-
algesia. PKC stimulation has been also 
implicated in the process of acute toler-
ance to opioid analgesia (16-18).
The problems with perioperative opioids 
have been well recognized (1,2,4,19,20), 
and these agents today are considered 
as being very far from ideal analge-
sics for pain after surgery. It is evident 
that the traditionally recognized opioid-
related side effects (prolonged drowsi-
ness, sedation, nausea, vomiting and 
gastrointestinal tract dysfunction) may 
significantly delay recovery, provide 
additional sources of postoperative 
distress and morbidity, and demand 
additional costs and resources for 
effective management. In contrast, 
attempts aiming to improve postopera-
tive analgesia with non-opioid analge-
sics and techniques, result in opioid 
sparing effect, reduce side-effects and 
morbidity, improve patient satisfaction 
and decrease length of hospitalization 
or stay in the recovery.
Gabapentin
Gabapentin (1-(amino-methyl)-cyclo- 
hexane acetic acid) is a novel antiepilep-
tic agent that has proved to be especially 
effective at relieving allodynia and hyper-
algesia in animal models. Furthermore, 
it has been shown to be efficacious in 
numerous small clinical studies and case 
reports in a wide variety of neuropathic 
pain syndromes, as well as other types 
of pain (21). Specifically, gabapentin has 
been clearly demonstrated to be effec-
tive for the treatment of neuropathic pain 
in diabetic neuropathy (22,23), posther-
petic neuralgia (24), trigeminal neuralgia 
(25), painful neuropathy from HIV infec-
tion (26), cancer (27-29), and complex 
regional pain syndromes (30,31). This 
supportive evidence, combined with 
the drug’s favourable side-effect profile 
in various patient groups (including the 
elderly) and lack of drug interactions, 
has rendered it an attractive agent for 
clinical practice. Gabapentin’s exact 
mechanism of action is not quite clear, 
but most likely involves inhibition of neu-
ronal voltage-gated calcium currents 
(VGCC) and suppression of excitatory 
neurotransmitter release.
Gabapentin was originally developed as 
a gamma-aminobutyric acid (GABA)-
mimetic compound. The molecular 
weight of the drug is 171.34, and at 
physiological pH it is highly charged, 
existing as a zwitterion with two pKa 
values of 3.68 and 10.70 (21).
Although it is stable at room tempera-
ture, a small amount of lactam forma-
tion occurs in aqueous solutions and 
this is minimized at a pH of 6.0.
Gabapentin, available only as oral prep-
arations, is absorbed in the small intes-
tine by a combination of diffusion and 
facilitated transport. Its transport from 
the gut is facilitated by its binding to a 
receptor linked to a saturable l-amino 
acid transport mechanism (32-34). 
Brain tissue concentrations are 80% 
the plasma level. In humans it exists in a 
highly ionized state at physiological pH 
(21). Gabapentin is not metabolized in 
humans and is eliminated unchanged 
in the urine. It undergoes first-order 
kinetic elimination and renal impairment 
decreases gabapentin elimination in 
a linear fashion with a good correla-
tion with creatinine clearance. Unlike 
other anticonvulsant drugs, it does not 
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induce or inhibit hepatic microsomal 
enzymes.
Despite a remarkably successful and 
safe clinical profile, the drug’s exact site 
or mode of mechanism has not been 
completely understood (35). In experi-
mental animals gabapentin exerts a 
potent inhibitory effect in neuropathic 
pain models of mechanical hyperalge-
sia and mechanical/thermal allodynia. 
So far, there is no evidence that gabap-
entin blocks GABA uptake or metabo-
lism that it binds to GABAA or GABAB 
receptors, or exerts any GABA-mimetic 
action (35,36).
Other effects of gabapentin have been 
described but are not considered to play 
a significant role with regard to phar-
macodynamics. These include small 
decreases in the release of monoamine 
neurotransmitters (dopamine, noradren-
aline and serotonin) (37,38), and the 
attenuation of sodium-dependent action 
potentials (suggesting sodium channel 
blockade) after prolonged exposure to 
the drug (39).
Although early studies indicated a cen-
tral anti-allodynic effect (40), gabapentin 
has been shown to inhibit ectopic dis-
charge activity from injured peripheral 
nerves, as well (41). With regards to site 
of action, Patel et al. demonstrated a 
presynaptic site of action for gabapentin 
in the rat spinal cord (42). Field et al. 
excluded an antihyperalgesic action via 
opioid receptor binding, after demon-
strating that morphine tolerance does 
not alter the efficacy of gabapentin, and 
naloxone does not reduce its antihyper-
algesic effect (43). Receptor binding 
studies have also failed to demonstrate 
a direct binding site for gabapentin at the 
NMDA receptor (44).
It has also been recognized that the α2δ 
subunit of the voltage-gated calcium 
channels is a binding site for gabap-
entin and the S-isomer of pregabalin 
(S-(+)-3-isobutylgaba) (45). Because 
only gabapentin and the S-isomer of 
pregabalin produce antihyperalgesic 
effects, it has been postulated that the 
antihyperalgesic action for gabapentin 
is mediated by its binding to this site 
on the voltage-gated calcium channel 
(46). The α2δ subunit regulates the 
conductance of current flow through 
the voltage-gated calcium chan-
nels (47). Thus, an inhibitory effect of 
gabapentin on the neuronal calcium 
channels (especially certain VGCC 
subtypes, such as P/Q and/or N type) 
might decrease calcium influx, which 
might subsequently reduce excitatory 
amino acid (glutamate) release, lead-
ing to decreased postsynaptic exci-
tatory responses (48-51). Otherwise, 
an enhancement of the calcium influx 
via VGCC produced by gabapentin, 
in case of a possible enhancement of 
VGCC as a result of binding to the α2δ 
subunit might alternatively reduce the 
membrane excitability by facilitating K+ 
efflux via the calciumactivated potas-
sium channels that have been identified 
on mammalian sensory nociceptive 
neurons and are altered by nerve injury 
(52). These speculations may be con-
sistent with the hypothesis that gabap-
entin modifies voltage-gated calcium 
channels, in a manner consistent with 
explaining an antihyperalgesic effect by 
either mechanism.
Available studies investigating the 
effects of gabapentin on calcium cur-
rents in  neuronal cells initially produced 
controversial results (44,53,54). How-
ever, Sarantopoulos et al investigated 
the effects of gabapentin on the cal-
cium currents in primary afferent neu-
ronal somata, dissociated from rats 
with experimental nerve injury, sham 
skin surgery or non-operated, and 
employing special perforated patch 
recordings using β-escin (55), first 
showed that gabapentin inhibits volt-
age-gated calcium currents (56), but 
not ATP-sensitive potassium currents 
(KATP) (57). These KATP currents may 
also control excitability and excitatory 
neurotransmitter release from primary 
afferent terminals (58-63). Of note is 
the fact that gabapentin acts as a KATP 
channel opener in central neurons (58-
60), wherein inhibits neurotransmitter 
release via this mechanism, but most 
likely this is not the case on peripheral 
nociceptive pathways (57). Neverthe-
less, the gabapentin effect on VGCC 
is rapid, concentration-dependent and 
reversible, and the inhibition is partly 
voltage dependent (56). Apparently, 
the antihyperalgesic effect of gabapen-
tin may be explained by the inhibitory 
action on voltage-gated calcium chan-
nels. Inward calcium currents have a 
well-demonstrated role in mediating 
several neuronal physiological proc-
esses (64,65) including synaptic neu-
rotransmitter release (66,67), and are 
altered by nociception and neuronal 
injury (68,69). Additionally, other stud-
ies have suggested that gabapentin 
decreases excitatory neurotransmitter 
release at presynaptic dorsal horn sites 
(42,51), a consequence of VGCC inhibi-
tion. Inhibition of excitatory neurotrans-
mitter release in the spinal cord may 
prevent the development of central sen-
sitization and possibly the subsequent 
establishment of chronic pain.
 The pharmacological effects of gabap-
entin most likely are complex, and have 
been shown to be mediated at central 
(40,70), as well as at peripheral sites 
(46,56). In addition to neuropathic pain, 
gabapentin has also been shown to 
suppress pain from inflammatory mec-
hanisms, in a selective and preferen-
tial fashion (71). Stanfa et al reported 
opposing effects of this drug between 
normal animals, versus animals with 
painful inflammation: while gabapentin 
facilitates noxious evoked responses 
of dorsal horn neurons in the normal 
animals, in contrast, after inflammation 
inhibits C-fibres evoked responses and 
post-discharges, in a fashion indicative 
of a selective action against inflammatory 
pain states (71). Kanai et al showed that 
gabapentin has pro-excitatory effects 
in normal peripheral sensory neurons, 
while in injured neurons decreases excit-
ability (72). Sarantopoulos et al showed 
that gabapentin decreased VGCC in 
neurons dissociated from rats subjected 
to experimental surgical nerve injury and 
sham skin-operated rats, as well as in 
neurons from non-operated rats. Never-
theless, the gabapentin inhibitory effect 
in the latter was not as significant as in 
neurons from rats that had been previ-
ously subjected to surgical sciatic nerve 
injury or sham skin surgery (56). Further-
more, gabapentin suppresses thermal 
and mechanical hyperalgesia induced in 
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a surgical pain model by incision at the 
rat paw (73,74). Clinically, also, cutane-
ous secondary hyperalgesia (indicative 
of central sensitization) induced by heat 
and capsaicin application in volunteers, 
can be suppressed or prevented by 
gabapentin (75).
Because central sensitization may be 
associated with the development of 
at least some manifestations of early 
postoperative pain, as well as with the 
transition to chronic pain, drugs pos-
sessing antihyperalgesic action may 
suppress both phases of pain.
Considering the antihyperalgesic prop-
erties of gabapentin, particularly its 
capacity to selectively affect nocicep-
tive processes leading to central sen-




The above findings indicate a poten-
tial role of gabapentin as a putative 
“broadspectrum” analgesic (76,77), 
with a selective antihyperalgesic and 
antiallodynic action, specifically against 
pain induced intraoperatively by nerve 
or tissue injury (77). Gabapentin, may 
also suppress central sensitization, a 
major mechanism mediating the transi-
tion from acute to chronic pain after sur-
gery, perhaps via an inhibitory effect on 
VGCC that control presynaptic excitato-
ry neurotransmitter release. Pertinent to 
the above observation, is the emerging 
role of gabapentin as a perioperative 
and postoperative analgesic. The anti-
nociceptive and antihyperalgesic and 
anti-inflammatory effects of gabapentin 
in states that emerge after acute nerve 
injury may have an impact on acute and 
chronic pain after surgery. Because of 
the synergism between gabapentin and 
opioids, the effects of gabapentin on 
acute postoperative pain and morphine 
consumption in patients undergoing 
different types of surgery have been 
investigated in randomized, controlled 
double-blind studies. The postopera-
tive analgesic effect has been actu-
ally confirmed by systemic reviews that 
have analyzed series of clinical studies, 
evaluating gabapentin as a postopera-
tive analgesic agent (78). These stud-
ies have confirmed that perioperative 
gabapentin is an effective analgesic 
and has an opioid sparing effect. The 
specific effect after different types of 
surgery is reviewed in the following sec-
tions.
Pain after breast surgery
Two thirds or more of women who 
undergo breast surgery for cancer will 
develop chronic pain (7-10,79-81). In 
addition to physical discomfort, women 
experiencing chronic pain, after breast 
surgery for cancer, have poor quality of 
life, with impaired function and increased 
psychosocial distress (82-84).
Ongoing, intense acute postoperative 
pain may be associated with the devel-
opment of chronic pain after breast 
surgery. In this context, regarding the 
efficacy of gabapentin in preventing 
the development of chronic pain, two 
pertinent studies by Fassoulaki et al 
have also documented a preventative 
effect of perioperative gabapentin after 
breast surgery for cancer.
First, Fassoulaki et al investigated the 
analgesic efficacy of mexiletine and 
gabapentin on acute and chronic pain 
after breast surgery for cancer in 75 
patients (79).
They were randomized to receive, in a 
double-blind manner, mexiletine 600 
mg/d, or gabapentin 1200 mg/d or pla-
cebo for 10 days. A significant reduc-
tion of postoperative analgesic require-
ments in patients who received mexilet-
ine or gabapentin were observed.
Mexiletine and gabapentin reduced 
codeine consumption from the second 
to tenth day by 50%. Total paracetamol 
consumption was also reduced during 
the same time. Pain at rest was reduced 
by either drug on the third postoperative 
day, while gabapentin reduced postop-
erative pain after movement from the 
second to fifth postoperative day. No 
side effects, such as dizziness, drowsi-
ness, or ataxia were observed. Three 
months later, the incidence of burning 
pain was more frequent in the control 
group, indicating a preventative effect 
of perioperative gabapentin on chronic 
pain as well.
Of note is the finding that in the previous 
study, gabapentin, although started the 
day before surgery, decreased pain and 
produced an analgesic sparing effect 
only during and after the second post-
operative day. Nevertheless, this was 
not the case in a similar randomized, 
double-blind, placebo-controlled study 
by Dirks et al, who administered a single 
oral dose of gabapentin (1200 mg) or 
placebo 1 hour before mastectomy (85).
Gabapentin produced a opioid-spar-
ing effect (morphine consumption 
decreased by 50%) as well as a signifi-
cant analgesic effect, evident even at 2 
and 4 hours postoperatively.
Pain with movement decreased by 50% 
or more, while pain at rest and side 
effects did not differ.
Fassoulaki et al, also, in a double-blind, 
randomized controlled study, com-
pared a multimodal analgesic regimen 
(gabapentin, Eutectic Mixture of Local 
Anaesthetics -EMLA cream- applied to 
surgical field, and ropivacaine installa-
tion in the brachial plexus area) to pla-
cebo (9). Gabapentin was administered 
at a dose 400 mg orally every 6 hours 
starting from the day before surgery up 
to the eighth postoperative day. The 
group of patients that received gabap-
entin perioperatively, as part of a multi-
modal regimen, consumed much less 
analgesics immediately postoperative-
ly, had less pain at rest on postoperative 
days 1, 3 and 5, less pain after move-
ment in the PACU and on postoperative 
days 2,4 and 8, as well as a significantly 
lower incidence of chronic pain three 
months after surgery (45% versus 82% 
in the control group). The capacity of 
gabapentin to prevent chronic pain was 
attributed to suppression of the ectopic 
discharge activity from injured periph-
eral nerves and blockade of the injury-
induced neuronal hyperactivity.
Post-hysterectomy pain
The effect of gabapentin on postopera-
tive pain and analgesic requirements 
following abdominal hysterectomy, a 
common surgical procedure, has been 
investigated by a series of studies, not 
necessarily yielding consistent results.
Dierking et al, in a randomized, dou-
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ble-blind study investigated the opi-
oid sparing and analgesic effects of 
gabapentin administered during the 
first 24 h after abdominal hysterectomy 
(86). Gabapentin 1200 mg versus pla-
cebo was administered 1 h before sur-
gery, followed by 600 mg (or placebo) 
after 8, 16 and 24 hours. While pain 
levels remained the same, gabapentin 
reduced total postoperative morphine 
consumption in a fashion dependent 
on the plasma levels of the drug. No 
side-effects were detected.
Pain relieving and analgesic-sparing 
effects have been observed also even 
after a single preoperative dose of the 
drug. A randomized, placebo-controlled, 
double-blind study by Turan et al inves-
tigated whether a single dose of 1200 
mg gabapentin, administered one hour 
before surgery, affects pain and trama-
dol consumption after abdominal hys-
terectomy (87). Gabapentin decreased 
both pain scores up to 20 h after sur-
gery, as well as tramadol consumption 
at 12, 16, 20, and 24 h, including total 
consumption compared with placebo 
group. Sedation scores were similar at 
all the measured times. There were no 
differences between groups with regard 
to sedation and any side effects.
Furthermore, Rorarius et al, also in a 
double-blind, randomized controlled 
investigation compared 1200 mg of 
gabapentin to active placebo (15 mg 
of oxazepam) administered 2.5 h prior 
to induction of anaesthesia to patients 
undergoing elective vaginal hysterec-
tomy (88). Gabapentin reduced post-
operative analgesic consumption by 
40% during the first 20 postoperative 
hours, pain scores during the first 2 
postoperative hours, as well as postop-
erative nausea and vomiting (because 
of the decreased postoperative opioid 
requirements and/or of an anti-emetic 
effect). Nevertheless, oxazepam was 
more effective anxiolytic. As was the 
case in the previous studies, no differ-
ences were observed in side effects.
Gilron et al evaluated the effects of 
gabapentin alone (1800 mg/day), or 
in combination with rofecoxib (1800/50 
mg/day respectively), or rofecoxib alone 
(50 mg/day), versus placebo starting 1 
hour before abdominal hysterectomy 
and continuing for 72 hours (89). All 
treatments decreased pain at rest and 
movement at 24 hours and morphine 
consumption at 48 hours, and improved 
respiratory function measured by peak 
expiratory flow. Gabapentin was effica-
cious in reducing pain interference with 
movement, mood and sleep. Combi-
nation with rofecoxib was superior to 
either single agent for postoperative 
pain. Thus, combination with other 
non-opioid analgesics may confer sig-
nificant benefits such as opioid sparing, 
reduced interference with movement, 
mood and sleep and accelerated pul-
monary recovery.
Turan et al found similar results, with 
gabapentin 1200 mg/d alone, in com-
bination with 50 mg/d rofecoxib and 
rofecoxib alone, versus placebo, admi-
nistered before and for 2 hours after 
abdominal hysterectomy (90). All three 
treatments decreased pain scores 
and produced an opioid sparing effect 
versus control, which led to a faster 
recovery of bowel function. Seventy-two 
hours postoperatively, patients who 
had received combination treatment 
reported the highest satisfaction rate. 
Both these studies indicate a significant 
potential of the gabapentin as part of 
multimodal analgesia schemes facili-
tating recovery after lower abdominal 
surgical procedures.
These results are not reproducible by all 
studies. Fassoulaki et al investigated the 
effects of gabapentin 400 mg 6 hourly 
or placebo, administered from 18 hours 
preoperatively and continued for 5 post-
operative days, on acute as well as on 
chronic postoperative  pain one month 
after abdominal hysterectomy as well 
(91). Gabapentin had no effect on the 
acute postoperative pain and on postop-
erative analgesic requirements. Never-
theless, chronic pain in the surgical area 
one month after surgery was decreased 
from 81% in the control group to 36% in 
the gabapentin group. The intensity of 
pain at that time was also decreased. 
The same investigators evaluated the 
combination of gabapentin 400 mg 6 
hourly for 7 days with continuous wound 
irrigation with 0.75% ropivacaine for 30 
hours, versus placebo (92). In combi-
nation with local aesthetic, gabapentin 
did produce an early analgesic effects 
as well, evident in a significant opioid 
sparing effect starting immediately after 
surgery and continuing for up to the 
7th postoperative day. In addition, one 
month postoperatively fewer patients in 
the treatment group experienced chron-
ic pain than in the control group.
Pain after spinal surgery
The potential analgesic and opioid-
sparing effect of gabapentin was evalu-
ated also after spinal surgery, but differ-
ent studies yield controversial results. 
In a relevant randomized, placebo-con-
trolled, double-blind study, Turan et al 
investigated 1200 mg of gabapentin, 
administered 1 h before spinal surgery 
(elective lumbar discectomy or spinal 
fusion), versus placebo. Gabapentin 
resulted in a significant analgesic effect 
at 1, 2 and 4 hours after surgery, a mor-
phine-sparing effect, as well as reduc-
tion in the incidence of vomiting and 
urinary retention (93).
Pandey et al, similarly, reported that 
gabapentin (300 mg) administered 
prior to single-level lumbar discoid-
ectomy significantly decreased both 
the severity of postoperative pain at all 
time intervals up to 24 hours, as well as 
postoperative opioid requirements dur-
ing the same time interval (94).
However, in another randomized-con-
trolled, double-blind study gabapentin 
800 mg administered preoperatively 
before elective lumbar laminectomy or 
discectomy failed to decrease pain or 
morphine requirements in the immedi-
ate postoperative period after lumbar 
laminectomy and discectomy (95).
It is unlikely that this discrepancy may 
be explained by the a dose-response 
effect, as in the study by Pandey et al, 
a much lower dose of 300 mg resulted 
in a positive effect. Furthermore, in a 
dose-response study, gabapentin, up 
to 600 mg, 2 hours before surgery pro-
duced an analgesic and opioid spar-
ing effect versus placebo in a dose-
dependent manner (96). Increasing the 
dose of gabapentin from 600 to 1200 
mg did not decrease pain, or opioid 
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requirements any further. So, based on 
these results, gabapentin 600 mg is the 
optimal dose for postoperative analge-
sia after lumbar discectomy.
Post-amputation pain
Pain in the stump of the residual limb 
(stump pain), or referred to the miss-
ing limb (phantom pain) frequently 
follows amputation, affecting a high 
percentage (60%- 80%) of amputees 
(97-100). Although the prevalence of 
both of these painful syndromes sub-
sides over time, some patients con-
tinue suffering from pain, of intensity 
severe enough to affect their quality of 
life. Post-amputation pain syndromes 
are usually difficult to treat. Tricyclic 
antidepressants have shown equivocal 
efficacy and their use may be limited 
by side effects, but monotherapy with 
gabapentin up to 2400 mg daily was 
better than placebo in relieving phan-
tom pain at 6 weeks’ treatment (101). 
Thus, Nikolajsen et al investigated 
whether postoperative treatment with 
gabapentin could reduce postamputa-
tion stump and phantom pain (102). 
Patients received placebo, or gabapen-
tin started on the first postoperative day 
after amputation, gradually increased 
up to 2400 mg/day, and continued for 
30 days. However, gabapentin failed 
to reduce the incidence or intensity of 
post-amputation pain, at short term (30 
days) or long term (up to 6 months).
Pain after orthopedic 
surgery
Gabapentin in most previous studies 
decreased postoperative pain (including 
pain with movement) and/or postopera-
tive opioid consumption, but these stud-
ies did not include any patients requir-
ing mobilization after joint surgery. To 
investigate the gabapentin effect in the 
latter patient population, Menigaux et al 
administered 1200 mg oral gabapentin 
or placebo 1-2 h before anterior cruciate 
ligament repair under general anaes-
thesia (103). Gabapentin decreased 
preoperative anxiety scores; postop-
erative pain scores (both at rest and 
after mobilization and physiotherapy) at 
days 1 and 2, and was associated with 
more extensive range of motion and less 
morphine consumption within the same 
time interval. In addition, the same group 
of authors, administered oral gabap-
entin 800 mg versus placebo, 2 hours 
before arthroscopic shoulder surgery, 
but in this case the drug did not augment 
postoperative analgesia provided by 
interscalene brachial plexus (104).
Pain after Ear, nose and throat (ENT) 
surgery In a randomized, double-blind, 
placebo-controlled study, Mikkelsen 
et al investigated the effect of gabap-
entin 1200 mg before tonsillectomy in 
adults, followed by gabapentin 1200 
mg on the day of operation and 1800 
mg for the next 5 days, versus placebo, 
in combination with rofecoxib 50 mg 
daily (105). Gabapentin reduced res-
cue opioid analgesic requirements the 
first 24 hours, but at the cost of more 
side effects such as dizziness, gait dis-
turbance and vomiting.
Turan et al reported that gabapentin 
(1200 mg 1 h before rhinoplasty or endo-
scopic sinus surgery under monitored 
anaesthesia care) conferred significant 
intraoperative and postoperative analge-
sia and reduced opioid and non-opioid 
analgesic requirements, but at cost of 
higher incidence side-effects (106).
Pain after other surgical 
procedures
Pain after laparoscopic cholecystec-
tomy Gabapentin administered preop-
eratively significantly decreases post-
operative pain and analgesic require-
ments following laparoscopic chole-
cystectomy. Pandey et al administered 
300 mg gabapentin, 100 mg tramadol 
or placebo in a double-blind manner 
two hours before laparoscopic chole-
cystectomy under general anaesthesia. 
Gabapentin decreased pain and opioid 
requirements at all time intervals com-
pared to tramadol and placebo, but 
more sedation, nausea and vomiting 
were a drawback (107).
Post-thoracotomy pain
Pain with neuropathic characteristics, 
commonly ensues after thoracic surgery 
and trauma, and it may be refractory 
to conventional analgesic strategies. 
Sihoe et al. tried gabapentin on 60 con-
secutive patients with refractory pain 
persisting at four weeks or more after 
thoracic surgery or trauma. Gabapentin 
may relieve refractory thoracic pain and 
paresthesiae in approximately 75% of 
patients (108). The incidence of minor 
side effects (somnolence and dizzi-
ness) was 40%, while overall satisfac-
tion rates were 90%.
Enhancement of epidural 
analgesia
Turan et al investigated gabapentin as 
an adjunct for postoperative analgesia 
using patient-controlled epidural anal-
gesia (PCEA) (109). In patients who 
received PCEA after lower extremity 
surgery procedures, gabapentin (1200 
mg daily before and for 2 days after sur-
gery) decreased pain scores at 1, 4, 8, 
12, and 16 h, PCEA bolus requirements 
at 24, 48 and 72 hours and paracetamol 
consumption, versus placebo.
However, time to return of bowel func-
tion, duration of hospitalization, and 
resumption of oral diet did not differ, 
while the incidence of dizziness was 
higher in the gabapentin group. Nev-
ertheless, despite more dizziness, 
patient satisfaction was higher amongst 
patients who received gabapentin.
Conclusion
Most of these studies have shown that 
either single preoperative or repeated 
doses of gabapentin, continued for up to 
a few days after surgery, decrease acute 
postoperative pain and/or need for post-
operative opioids. This has been shown 
for procedures such as abdominal and 
vaginal hysterectomy, breast surgery for 
cancer, lumbar discectomy and spinal 
fusion, laparoscopic cholecystectomy, 
orthopedic surgery and ENT surgery. 
Reduced opioid consumption may trans-
late into fewer opioid related unwanted 
effects with an impact on postoperative 
recovery, but this is not quite clear yet. 
In a few studies, gabapentin resulted 
in side effects such as dizziness and 
drowsiness. More studies are needed to 
determine the optimal dose and dura-
tion of administration for different types 
of surgery, especially considering the 
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